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Background: The potential of secretory leukocyte protease inhibitor (SLPI) as a biomarker for colorectal cancer was
studied. A prospective, randomized, controlled, clinical trial was conducted in 2013 and 2014 to confirm whether
the expression of SLPI correlates with prognosis and metastasis in colorectal cancer patients.
Methods: Immunohistochemistry was used to detect SLPI expression in colorectal cancer. The expression of SLPI
was scored by two pathologists independently. Statistical analysis of the data was performed using a χ2 test to
investigate the influence of SLPI on the pathologic characteristics of colorectal cancer.
Results: Compared with normal tissue, SLPI was overexpressed in colorectal cancer tissue. Overexpression of SLPI
correlated with different grades (moderate or good differentiation: 2.7% low expression versus 97.3% high
expression, low differentiation: 41.7% low expression versus 58.3% high expression), TNM stage (I or II: 4.2% low
expression versus 95.8% high expression; III or IV: 19.7% low expression versus 80.3% high expression), lymphatic
metastasis (18.6% low expression versus 81.4% high expression) and distal metastasis (86.5% low expression versus
13.5% high expression), but not with patient age or sex (P = 0.613, P = 0.871).
Conclusions: Upregulated SLPI correlates with aggressive pathologic characteristics of colorectal cancer; SLPI could
be used as an indicator of progression and metastasis in patients with colorectal cancer.
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Colorectal cancer is one of the most common malignan-
cies worldwide and is a major cause of cancer-related
deaths [1]. Survival rates of patients with colorectal cancer
have increased in the past few years, possibly as a result of
earlier diagnosis and improved treatment regimens; none-
theless, approximately 30% to 50% of patients who un-
dergo curative resection subsequently experience local
tumor recurrence or metastasis [2,3].
The secretory leukocyte protease inhibitor (SLPI) is an
11.7-kDa, nonglycosylated, single-chain protein that is* Correspondence: guiyingliu@yeah.net
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cells, secretory cells of the salivary glands, and various
host inflammatory and immune cells, such as macro-
phages, neutrophils, and B lymphocytes [4-7]. However,
its potential as biomarker for colorectal cancer has not
been studied.
This study was a prospective, randomized, controlled,
clinical trial conducted in 2013 and 2014 to confirm
whether SLPI expression correlates with prognosis and
metastasis in colorectal cancer patients.Methods
Tumor tissues
A uniform cohort of 296 patients (162 men and 134
women) with colorectal cancer (6 with stage I, 112 with
stage II, 132 with stage III and 46 with stage IV cancer)This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Relationship between expression of SLPI and its
clinic pathological characteristic in colorectal cancer
Patients SLPI expression (%) χ2 P
High Low
Sex 0.013 0.871
Male 162 76 (46.9) 86 (53.1)
Female 134 65 (48.5) 69 (51.5)
Age (years) 0.241 0.613
>65 104 49 (47.1) 55 (52.9)
<65 192 101 (52.6) 91 (47.4)
Pathologic grade 38.143 <0.05
Good or moderate 260 253 (97.3) 7 (2.7)
Low 36 21 (58.3) 15 (41.7)
TNM grade 19.241 <0.05
I–II 118 113 (95.8) 5 (4.2)
III–IV 178 143 (80.3) 35 (19.7)
Lymphatic metastasis 25.174 <0.05
Positive 129 105 (81.4) 24 (18.6)
Negative 167 164 (98.2) 3 (1.8)
Distal metastasis 31.247 <0.05
Positive 37 5 (13.5) 32 (86.5)
Negative 259 232 (89.6) 27 (10.4)
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selected. All patients provided their consent for partici-
pation in the study, which was approved by the local
ethics committee. The age of the patients ranged from
24 to 87 years (mean: 53.3 years). Table 1 shows patients’
detailed information. Two cores of normal mucosa and
two cores of tumor tissue for each patient were paraffin-
embedded in ordered microarrays. Tumor microarrays
were sectioned in preparation for immunohistochemical
staining. Staining intensity was scored by two patholo-
gists separately. A score of 1 was used to signify low in-
tensity, a score of 2 signified intermediate intensity, and
a score 3 signified high intensity. A score of 0 to 2 indi-
cates low SLPI expression and a score of 3 indicates high
SLPI expression [8].A B 
Figure 1 Expression of SLPI in different tissues. (A) Normal colon tissue;Tissue preparation and staining
Specimens were fixed in 10% paraformaldehyde. Paraffin-
embedded tissue microarrays were incubated at 60°C prior
to de-waxing and rehydration. Antigen retrieval was
achieved by placing sections in 10 μM citric acid (pH 6)
and microwaving for 15 minutes. Endogenous peroxidases
were quenched in 15 ml hydrogen peroxide and 185 ml of
water. Samples were washed again with PBS prior to treat-
ment with Starting Block (Thermo Scientific, Rockford, IL)
for 10 minutes. Tissues were incubated in mouse anti-
human SLPI monoclonal antibody (1:50; Santa Cruz,
American). The primary antibodies were diluted in PBT
(10× PBS, 10% BSA, 10% Triton X-100 in double distilled
H2O) at 4°C overnight. Samples were washed with PBS
on the following day, incubated in secondary antibody
(1:1000), washed and then treated using a 3,3'-diamino-
benzidine (DAB) peroxidase staining kit (Shanghai Bio-
technology Company, NO132, Xuhui District, Shanghai
City, China) as per the manufacturer’s protocol. For detec-
tion, a DAB peroxidase detection kit was used and color
development was monitored using an optical microscope.
The development process was terminated by removing
DAB and rinsing the sections with ddH2O for 1 min prior
to counterstaining with hematoxylin.
Statistical analysis
Data are representative of three independent expe-
riments. SPSS20.0 software was used for statistical ana-
lysis. Statistical analysis of the data were performed
using the χ2 test. The differences were considered sig-
nificant at P < 0.05.
Results
In Figure 1, we can see negative expression of SLPI in
normal colon tissue (Figure 1A) and positive expression
of SLPI in poorly and well differentiated colon cancer
(Figure 1B,C).
As shown in Table 1, the expression of SLPI was not
correlated with age or sex (P = 0.613, P = 0.871). The
positive expression of SLPI was positively correlated
with the degree of tumor differentiation (P < 0.05). There
is significant correlation between SLPI and the TNMC 
(B) poorly differentiated colon cancer; (C) well differentiated colon cancer.
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tients with stage III or IV cancer was significantly higher
than that in stage I or II (P < 0.05). Moreover, the ex-
pression of SLPI in patients with distant metastasis is
higher than that without metastases (P < 0.05).
Discussion
The secretory leukocyte protease inhibitor gene is lo-
cated on chromosome 20q12-13.1 in human beings and
on chromosome 2H in mice, with a similar exon-intron
configuration [8]. Although physiologically unique and
designated as a protease inhibitor, SLPI has the struc-
tural characteristics of a WFDC domain. Chromosome
20q13 was recently recognized as the WFDC locus, con-
taining genes encoding 14 WFDC-type protease inhibi-
tors [9]. Secretory leukocyte protease inhibitor, which
has antimicrobial and anti-protease functions, belongs to
the whey acidic protein four-disulfide core family of pro-
teins, and is also produced in cancer tissues, but its role
in cancer is not well understood [10].
Bouchard et al. [11] reported that SLPI expression is
highly upregulated in pancreatic, papillary thyroid, uter-
ine cervix, endometrial, and ovarian cancer; by contrast,
SLPI is underexpressed in nasopharyngeal carcinoma,
bladder tumors, and some breast carcinomas, although
overexpression of this protein correlates with more in-
vasive forms of breast carcinoma. Devoogdt et al. [12]
reported that several factors, such as inflammatory cyto-
kines and steroid hormones, affect SLPI gene expression.
Hoskins et al. [13] reported that SLPI stimulates ovarian
cancer invasion, modulated in part by its serine protease
inhibitory activity, attenuating MMP-9 release.
This study investigated the potential clinical utility of
SLPI to serve as a prognostic and metastasis-predictive
biomarker in patients with colorectal cancer. We per-
formed independent validation experiments using a large
cohort of samples from 296 patients with colorectal can-
cer. These data provide strong evidence that SLPI is
overexpressed in colorectal cancer tissue. Overexpres-
sion of SLPI is correlated with tumor grade and TNM
stage, but not with patient age or sex. Our data are of
particular interest because they highlight that over-
expression of SLPI provides a predictor of lymphatic me-
tastasis and distant metastasis.
Conclusions
The high expression level of SLPI detected by immuno-
histochemistry in colorectal cancer showed that it corre-
lated with poorly differentiated colorectal cancer with a
TNM stage of III or IV, lymphatic metastasis and distal
metastasis. Collectively, these results indicate that eva-
luation of SLPI expression in patients with colorectal
cancer presents a clinically promising biomarker that
can facilitate disease risk assessment and severity inpatients with colorectal cancer. It could be used as an
indicator for progression and metastasis of colorectal
cancer. However, further studies should be undertaken
to verify whether SLPI can become a new indicator for
colorectal cancer recurrence and survival of patients.
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